Vaxart (NASDAQ: VXRT)
Vaxart Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vaxart Company Info
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.
News & Analysis
Investing in Coronavirus Vaccine Stocks
Learn about the companies that are manufacturing COVID-19 vaccines and what you should know before investing in coronavirus vaccine stocks.
Could This Unknown Stock Beat Moderna in 2023?
Vaxart is still in the coronavirus vaccine race, even though its competitors remain very far ahead.
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
These players may change the world of medicine.
Can This 1 Thing Hurt Vaxart?
The company still is far from the vaccine race finish line.
Is Vaxart the Next Moderna?
The similarities are striking.
3 No-Brainer Stocks to Buy Right Now for Less Than $6
These stocks are all about cutting-edge technology.
Is It Too Late to Buy Vaxart Stock?
The past 12 months have been difficult for the biotech stock.
These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals
Vaxart is winning in two crucial areas.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.